# US 11,439,635 B2 · B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,635 B2
- Document ID: US11439635B2
- Status: Granted
- Kind: B2
- Application number: 16/943,519
- Filed: 2020-07-30
- Published: 2021-02-04
- Granted: 2022-09-13
- Earliest claimed: 2019-07-30
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Grant D. Barish; Meredith A. Sommars; Madhavi D. Senagolage
- Web page: https://patentgrep.com/patent/US11439635B2

## CPC

- A61K 31/4725: containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are methods and compositions for treating diabetes mellitus and non-alcoholic fatty liver disease by administering a therapeutic agent that inhibits the biological activity of B cell lymphoma 6 protein (BCL6).

## Claims

### Claim 1

A method for treating non-alcoholic fatty liver disease in a subject in need thereof, the method comprising administering to the subject a therapeutic agent that inhibits the expression of B cell lymphoma protein 6 (BCL6).

### Claim 2 (depends on 1)

The method of claim 1, comprising inhibiting expression of BCL6 in adipocytes.

### Claim 3 (depends on 1)

The method of claim 1, comprising inhibiting expression of BCL6 in hepatocytes.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method promotes insulin sensitivity.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method prevents hepatic steatosis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method enhances glucose tolerance.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method enhances glucose-stimulated insulin secretion.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method prevents weight gain.